journal
MENU ▼
Read by QxMD icon Read
search

Breast: Official Journal of the European Society of Mastology

journal
https://www.readbyqxmd.com/read/29328943/interval-breast-cancers-in-the-screening-with-tomosynthesis-or-standard-mammography-storm-population-based-trial
#1
Nehmat Houssami, Daniela Bernardi, Francesca Caumo, Silvia Brunelli, Carmine Fantò, Marvi Valentini, Giovanna Romanucci, Maria A Gentilini, Manuel Zorzi, Petra Macaskill
BACKGROUND & METHODS: The prospective 'screening with tomosynthesis or standard mammography' (STORM) trial recruited women participating in biennial breast screening in Italy (2011-2012), and compared sequential screen-readings based on 2D-mammography alone or based on tomosynthesis (integrated 2D/3D-mammography). The STORM trial showed that tomosynthesis screen-reading significantly increased breast cancer detection compared to 2D-mammography alone. The present study completes reporting of the trial by examining interval breast cancers ascertained at two year follow-up...
January 9, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29324303/first-line-vs-second-line-fulvestrant-for-hormone-receptor-positive-advanced-breast-cancer-a-post-hoc-analysis-of-the-confirm-study
#2
Angelo Di Leo, Guy Jerusalem, Roberto Torres, Didier Verhoeven, Kelly Pendergrass, Luca Malorni, Jasmine Lichfield, Miguel Martin
OBJECTIVES: The double-blind, phase III CONFIRM study (NCT00099437) evaluated fulvestrant 500 mg vs fulvestrant 250 mg in postmenopausal women with hormone receptor-positive locally advanced/metastatic breast cancer (LA/MBC). This post-hoc analysis investigated the efficacy and safety of fulvestrant given either first-line or second-line for advanced disease. MATERIALS & METHODS: Progression-free survival (PFS) and overall survival (OS) with fulvestrant 500 mg vs fulvestrant 250 mg was evaluated using unadjusted log-rank tests in patients treated in the first- (progression during or within 12 months after completing adjuvant endocrine therapy; n = 387) and second-line (following endocrine therapy for LA/MBC; n = 343) settings...
January 8, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29324302/addressing-the-paradox-of-increasing-mastectomy-rates-in-an-era-of-de-escalation-of-therapy-communication-strategies
#3
REVIEW
Mona P Tan, Edibaldo Silva
Breast conservation therapy (BCT) was established as the preferred modality of surgical treatment for early stage breast cancer in the early 1990's. Yet, rising mastectomy rates have been observed over the last decade. This increase is a cause for concern as recent large population-based studies have consistently reported improved breast cancer-specific survival and local control rates with BCT, in comparison with mastectomy. There is a pressing need to formulate strategies to effectively inform both patients and practitioners about current data, in the hope of reversing rising mastectomy rates to optimise survival outcomes...
January 8, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29316513/the-biology-of-male-breast-cancer
#4
REVIEW
Ian S Fentiman
Important differences have begun to emerge concerning the molecular profile of female and male breast cancer which may prove to be of therapeutic value. This review examined all the available data on the genomics of MBC. Most male cancers are ER+ve but without a corresponding increase in PR positivity and only a weaker association with estrogen-controlled markers such as PS2, HSP27 and Cathepsin-D. HER2 +ve cancers are rare in males and the role of androgen receptor is controversial. Although the Luminal A phenotype was the most frequent in both MBC and FBC, no Luminal B or HER2 phenotypes were found in males and the basal phenotype was very rare...
January 6, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29310037/a-nationwide-registry-based-cohort-study-of-the-mammaprint-genomic-risk-classifier-in-invasive-breast-cancer
#5
Floris H Groenendijk, Agnes Jager, Fatima Cardoso, Carolien H M van Deurzen
AIM: To evaluate the use of the MammaPrint assay, a 70-gene risk signature for early breast cancers, and to correlate genomic risk stratification with individual clinicopathological parameters and clinical risk as assessed by Adjuvant! Online. METHODS: A Dutch Pathology Registry (PALGA)-based cohort study consisting of 1916 patients for which 1946 MammaPrint assay results were synoptically reported from 2013 to 2016. We could retrospectively assess clinical risk for 1146 tumors (58...
January 5, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29310036/pleomorphic-lcis-what-do-we-know-a-uk-multicenter-audit-of-pleomorphic-lobular-carcinoma-in-situ
#6
Yazan A Masannat, Ehab Husain, Rebecca Roylance, Steven D Heys, Pauline J Carder, Hiam Ali, Yasmine Maurice, Sarah E Pinder, Elinor Sawyer, Abeer M Shaaban
AIMS: Pleomorphic lobular carcinoma in situ (PLCIS) is a relatively newly described pathological lesion that is distinguished from classical LCIS by its large pleomorphic nuclei. The lesion is uncommon and its appropriate management has been debated. The aim of this study is to review data from a large series of PLCIS to examine its natural history in order to guide management plans. MATERIALS AND METHODS: Comprehensive pathology data were collected from two cohorts; one from a UK multicentre audit and the other a series of PLCIS cases identified from within the GLACIER study cohort...
January 5, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29310035/combined-effects-of-neoadjuvant-letrozole-and-zoledronic-acid-on-%C3%AE-%C3%AE-t-cells-in-postmenopausal-women-with-early-stage-breast-cancer
#7
Tomoharu Sugie, Eiji Suzuki, Akira Yamauchi, Kazuhiko Yamagami, Norikazu Masuda, Naomi Gondo, Eriko Sumi, Takafumi Ikeda, Harue Tada, Ryuji Uozumi, Shotaro Kanao, Yoshimasa Tanaka, Yoko Hamazaki, Nagahiro Minato, Masakazu Toi
INTRODUCTION: Adjuvant bisphosphonates lead to better prognosis in postmenopausal breast cancer. However, the association between clinical outcomes and immune modulation by them is still unclear. METHODS: In this prospective, open-label phase II study, postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative early-stage breast cancer received neoadjuvant letrozole (LET) for one month, followed by treatment with a single dose of zoledronic acid...
January 5, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29306771/stage-specific-incidence-and-survival-of-breast-cancer-in-norway-the-implications-of-changes-in-coding-and-classification-practice
#8
Inger Kristin Larsen, Tor Åge Myklebust, Tom Børge Johannesen, Bjørn Møller, Solveig Hofvind
To describe the association between coding and classification practices and observed stage-specific incidence and survival trends in Norway over time. We identified all women diagnosed with invasive breast cancer in the period between 1980 and 2015. Changes in the coding and classification of breast cancer in the study period were described, and stage-specific incidence rates and relative survival were calculated. A total of 90 362 women were diagnosed with primary breast cancer, stage I-IV, or unknown stage, in the study period...
January 4, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29306176/incidence-and-tumour-characteristics-of-bilateral-and-unilateral-interval-breast-cancers-at-screening-mammography
#9
Rob M G van Bommel, Adri C Voogd, Joost Nederend, Wikke Setz-Pels, Marieke W J Louwman, Luc J Strobbe, Dick Venderink, Vivianne C G Tjan-Heijnen, Lucien E M Duijm
BACKGROUND: Detected by screening mammography, bilateral breast cancer has a different pathological profile compared to unilateral breast cancer. We investigated the incidence of bilateral interval breast cancers and compared their characteristics with those of unilateral interval breast cancers. METHODS: We included all 468,720 screening mammograms of women who underwent biennial screening mammography in the South of the Netherlands between January 2005 and January 2015...
January 3, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29289822/partial-breast-irradiation-the-time-is-there
#10
Icro Meattini, Lorenzo Livi, Stefania Pallotta, Livia Marrazzo
The conventionally fractionated partial breast irradiation (PBI) IMPORT LOW trial represents the perfect example of how an adequate selection of patients led to a minimal local relapse rate for patients. Coles and colleagues, demonstrated a 5-year non-inferiority local relapse rate for PBI compared to standard whole breast irradiation, together with a significant reduction in terms of breast toxicity using a conventional radiation technique implementable worldwide. Most of enrolled patients had early stage node negative, grade1-2, oestrogen receptor positive, human epidermal growth factor receptor 2 negative tumours...
December 28, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29287190/a-possible-role-of-fancm-mutations-in-male-breast-cancer-susceptibility-results-from-a-multicenter-study-in-italy
#11
Valentina Silvestri, Piera Rizzolo, Veronica Zelli, Virginia Valentini, Ines Zanna, Simonetta Bianchi, Maria Grazia Tibiletti, Liliana Varesco, Antonio Russo, Stefania Tommasi, Anna Coppa, Carlo Capalbo, Daniele Calistri, Alessandra Viel, Laura Cortesi, Siranoush Manoukian, Bernardo Bonanni, Marco Montagna, Domenico Palli, Paolo Radice, Paolo Peterlongo, Laura Ottini
INTRODUCTION: Breast cancer (BC) in men is a rare disease, whose etiology appears to be associated with genetic factors. Inherited mutations in BRCA1/2 genes account for about 10-15% of all cases. FANCM, functionally linked to BRCA1/2, has been suggested as a novel BC susceptibility gene. Our aim was to test if FANCM germline mutations could further explain male BC (MBC) susceptibility. METHODS: We screened the entire coding region of FANCM in 286 MBCs by a multi-gene panel analysis, and compared these data with available whole exome sequencing data from 415 men used as population controls...
December 26, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29287189/human-epidermal-growth-factor-receptor-2-dual-blockade-with-trastuzumab-and-pertuzumab-in-real-life-italian-clinical-practice-versus-the-cleopatra-trial-results
#12
Sabino De Placido, Mario Giuliano, Francesco Schettini, Claudia Von Arx, Giuseppe Buono, Ferdinando Riccardi, Daniela Cianniello, Roberta Caputo, Fabio Puglisi, Marta Bonotto, Alessandra Fabi, Domenico Bilancia, Mariangela Ciccarese, Vito Lorusso, Andrea Michelotti, Dario Bruzzese, Bianca Maria Veneziani, Mariavittoria Locci, Michelino De Laurentiis, Grazia Arpino
OBJECTIVES: Given their inclusion and exclusion criteria, randomized clinical trials (RCT) might not include a population that truly mirrors real life (RL). This raises concerns about the applicability of RCT results in clinical practice. We evaluated the efficacy of anti-HER2 treatment with pertuzumab combined with trastuzumab and a taxane as first-line treatment for HER2-positive metastatic breast cancer in a RL setting, and compared the safety results obtained in our population versus the experimental cohort of the CLEOPATRA RCT, which led to the approval of this therapy...
December 26, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29274475/breast-cancer-in-octogenarian-are-we-doing-our-best-a-population-registry-based-study
#13
David Martinez-Ramos, Laura Simon-Monterde, Raquel Queralt-Martin, Consuelo Suelves-Piqueres, Pedro Menor-Duran, Javier Escrig-Sos
BACKGROUND: The number of old people with breast cancer is estimated to increase during the next years in developed countries. However, management of breast cancer in octogenarians is not well established. The main objective was to evaluate if patients older than 80 years with breast cancer are receiving the most convenient treatment by using a population registry cancer analysis. PATIENTS AND METHODS: A retrospective analysis of a population cancer registry was designed...
December 20, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29253718/integration-of-radiation-and-immunotherapy-in-breast-cancer-treatment-implications
#14
REVIEW
Jason C Ye, Silvia C Formenti
Radiation therapy (RT) has been successfully used in the treatment of breast cancer (BC) for over a century. While historically thought to be immunosuppressive, new data have shown that RT can work together with the immune system to eliminate cancer. It can cause immunogenic cell death and facilitate tumor neoantigen presentation and cross-priming of tumor-specific T-lymphocytes, turning irradiated tumor into an in-situ vaccine. Unfortunately, due to various immune escape mechanism put in place by the tumor, RT alone rarely results in a systemic response of metastatic disease sites (known as the abscopal effect)...
December 15, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29248876/associations-between-adjuvant-radiotherapy-and-different-causes-of-death-in-a-german-breast-cancer-cohort
#15
Nadia Obi, Christine Eulenburg, Petra Seibold, Ursula Eilber, Kathrin Thöne, Sabine Behrens, Jenny Chang-Claude, Dieter Flesch-Janys
BACKGROUND: Studies of cohorts of breast cancer (BC) patients diagnosed before 1990 showed radiotherapy (RT) to be associated with increased cardiovascular (CVD) and lung cancer mortality many years after diagnosis. In the late 1990s, improvements in RT planning techniques reduced radiation doses to normal tissues. Recent studies did not consistently report higher RT-related mortality for CVD and second cancers. Aim of the study was to analyze specific causes of death after 3D-conformal RT in a recent BC cohort...
December 14, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29248875/development-and-psychometric-validation-of-a-shorter-version-of-the-breast-cancer-treatment-outcome-scale-bctos-12
#16
André Hennigs, Jörg Heil, Annette Wagner, Michelle Rath, Helfried Moosbrugger, Augustin Kelava, Michael Golatta, Sarah Hug, Fabian Riedel, Geraldine Rauch, Manuel Feißt
OBJECTIVES: Aesthetic and functional outcomes after oncoplastic breast-conserving surgery (BCS) are directly related to the patients' quality of life (QoL). The Breast Cancer Treatment Outcome Scale (BCTOS) is a validated but burdensome questionnaire for the assessment of these outcomes. The aim of the study was to strengthen and focus the BCTOS instrument by reducing the number of items and subscales without loss of information and validity. METHODS: This study used a dataset of 871 patients with stage 0 - III breast cancer, from a prospective cohort study, who underwent BCS...
December 14, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29246526/trends-and-predictions-to-2020-in-breast-cancer-mortality-americas-and-australasia
#17
Greta Carioli, Matteo Malvezzi, Teresa Rodriguez, Paola Bertuccio, Eva Negri, Carlo La Vecchia
OBJECTIVES: We considered trends in breast cancer mortality for 12 American and 8 Australasian countries during 1970-2014, and predicted rates for 2020. MATERIALS AND METHODS: We obtained official death certification data for breast cancer and population figures from the World Health Organization, Pan American Health Organization and United Nations databases. We derived age-standardized rates (world standard population), and predictions for 2020 using joinpoint regression...
December 12, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29232600/a-retrospective-review-of-phyllodes-tumours-of-the-breast-a-single-institution-experience
#18
Vithusha Ganesh, Leah Drost, Justin Lee, Bo Angela Wan, Liying Zhang, Eileen Rakovitch, Danny Vesprini, Elzbieta Slodkowska, K Liang Zeng, Philomena Sousa, Caitlin Yee, Henry Lam, Edward Chow
BACKGROUND: Phyllodes tumours are rare and histologically diverse, posing challenges in prognosis and treatment. Due to their rarity, they have seldom been studied. PURPOSE: The purpose was to investigate clinical practices in the management of phyllodes tumours, as well as patient outcomes to contribute to the limited body of knowledge surrounding these tumours. METHODS: A retrospective review was conducted on all patients with phyllodes tumours at a single institution...
December 9, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29227815/meta-analysis-of-flap-perfusion-and-donor-site-complications-for-breast-reconstruction-using-pedicled-versus-free-tram-and-diep-flaps
#19
REVIEW
Woonhyeok Jeong, Seongwon Lee, Junhyung Kim
OBJECTIVES: The transverse rectus abdominis musculocutaneous (TRAM) flap is an important option for breast reconstruction. Several studies have recently evaluated whether a greater number of complications result from the use of pedicled TRAM (pTRAM) flaps versus either free TRAM (fTRAM) flaps or deep inferior epigastric artery perforator (DIEP) flaps. To clarify the evidence regarding this issue, we performed an objective meta-analysis of published studies. MATERIALS AND METHODS: A literature search of articles published between January 1, 1990, to January 1, 2017 was performed using the PubMed, EMBASE, Scopus, and Cochrane databases...
December 8, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29223797/clinical-impact-of-adjuvant-radiation-therapy-delay-after-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer
#20
Saulo Brito Silva, Allan Andresson Lima Pereira, Gustavo Nader Marta, Kennya Medeiros Lopes de Barros Lima, Thiago Brasileiro de Freitas, Adriana Reis Brandão Matutino, Manoel Carlos Leonardi de Azevedo Souza, Renata Gondim Meira Velame de Azevedo, Pedro Antonio Hermida de Viveiros, Julianne Maria da Silva Lima, José Roberto Filassi, Heloísa de Andrade Carvalho, José Roberto Morales Piato, Max S Mano
BACKGROUND: and Purpose: Post-operative radiation therapy (PORT) is usually indicated for patients with breast cancer (BC) after neoadjuvant chemotherapy (NAC) and surgery. However, the optimal timing to initiation of PORT is currently unknown. MATERIAL AND METHODS: We retrospectively evaluated data from patients with BC who received PORT after NAC and surgery at our institution from 2008 to 2014. Patients were categorized into three groups according to the time between surgery and PORT: <8 weeks, 8-16 weeks and >16 weeks...
December 6, 2017: Breast: Official Journal of the European Society of Mastology
journal
journal
31139
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"